DHER:XETRDelivery Hero SE Analysis
Data as of 2026-03-11 - not real-time
€17.49
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Delivery Hero SE is trading at €17.49, far below its DCF‑derived fair value of roughly €116, indicating a substantial valuation gap. Technical indicators are bearish: the price sits under the 20‑day (≈19.33), 50‑day (≈22.30) and 200‑day (≈22.83) moving averages, RSI is at 36 and MACD shows a bearish divergence. Recent news amplified pressure as Talabat Holding Plc cut its 2026 outlook, triggering an 8% share‑price drop and highlighting margin‑compression concerns. Fundamentally, revenue grew 19% YoY to €13.4 bn, yet profitability remains weak with a negative profit margin and a trailing EPS of –€1.86. The company carries a high debt load (≈€4.6 bn) and a debt‑to‑equity ratio near 200%, but cash generation is positive, delivering €1.2 bn in free cash flow. Volatility is elevated (≈70% 30‑day) while beta is modest (≈0.47), suggesting price swings are driven more by company‑specific factors than market movements. The “Extreme Greed” sentiment index (≈77) signals strong investor appetite, yet the bearish technical backdrop tempers short‑term optimism. With a projected upside of over 60% relative to current levels, the stock presents a classic value‑play if the company can translate revenue growth into sustainable earnings. However, the high geographic exposure across 70 markets and the absence of a dividend add layers of risk. In summary, the stock is deeply undervalued on a discounted‑cash‑flow basis, but short‑term price action is constrained by recent margin concerns and technical weakness.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below all major moving averages
- Recent 8% drop after Talabat margin outlook cut
- Bearish MACD and RSI indicating continued downside pressure
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value suggests >60% upside
- Strong revenue growth (19% YoY) and positive free cash flow
- Improving forward EPS expectations
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Large addressable market across 70 countries
- Potential to improve margins as scale and advertising revenue rise
- Undervalued relative to intrinsic valuation despite high debt
Key Metrics & Analysis
Financial Health
Revenue Growth19.20%
Profit Margin-4.18%
P/E Ratio24.7
ROE-28.92%
ROA0.80%
Debt/Equity198.40
P/B Ratio2.4
Op. Cash Flow€930.5M
Free Cash Flow€1.2B
Technical Analysis
TrendBearish
RSI36.0
Support€16.72
Resistance€22.80
MA 20€19.33
MA 50€22.30
MA 200€22.83
MACDBearish
VolumeIncreasing
Fear & Greed Index76.98
Valuation
Fair Value€116.44
Target Price€28.61
Upside/Downside63.58%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.47
Volatility69.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.